Iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiin Wo 2011/161427 A3 Wo 2011/161427
Total Page:16
File Type:pdf, Size:1020Kb
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIN (10) International Publication Number (43) International Publication Date WO 2011/161427 A3 29 December 2011 (29.12.2011) PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 38/17 (2006.01) A61P 5/50 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 3/10 (2006.01) A61P 21/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61P 3/04 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/GB2011/000966 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 27 June 2011 (27.06.2011) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/358,596 25 June 2010 (25.06.2010) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/384,652 20 September 2010 (20.09.2010) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, 61/420,677 7 December 2010 (07.12.2010) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant (for all designated States except US): ASTON LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, UNIVERSITY [GB/GB]; Aston Triangle, Birmingham SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, B4 7ET (GB). GW, ML, MR, NE, SN, TD, TG). __ (72) Inventors; and Published: (75) Inventors/Applicants (for US only): TISDALE, — with international search report (Art. 21(3)) Michael, J. [GB/GB]; Wellcot, Star Lane, Claverdon, = Warwickshire CV35 8LW (GB). RUSSELL, Steven — before the expiration of the time limit for amending the [GB/GB]; 18 Victory Road, Wedensbury, West Midlands claims and to be republished in the event of receipt of = WS10 7RR(GB). amendments (Rule 48.2(h)) (74) Agents: HOLLYWOOD, Jane Constance et al.; Kilburn — with sequence listing part of description (Rule 5.2(a)) & Strode LLP, 20 Red Lion Street, London WC1R 4PJ (88) Date of publication of the international search report: 8 March 2012 A3 (54) Title: GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF 2011/161427 (57) Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-a2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents. WO WO 2011/161427 PCT/GB2011/000966 GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF BACKGROUND OF THE INVENTION 5 FIELD OF THE INVENTION [0001] The present invention relates generally to medicinal formulations and supplements, and more particularly, to formulations and methods for altering the metabolism of a subject, as well as ameliorating disorders such as cachexia, obesity, diabetes and insulin resistance. BACKGROUND INFORMATION 10 [0002] The prevalence of obesity in adults, children and adolescents has increased rapidly over the past 30 years in the United States and globally and continues to rise. Obesity is classically defined based on the percentage of body fat or, more recently, the body mass index (BMI), also called Quetlet index (National Task Force on the Prevention and Treatment of Obesity, Arch. Intern. Med., 160: 898-904 (2000); Khaodhiar, L. et al., Clin. Cornerstone, 2: 15 17-31 (1999)). The BMI is defined as the ratio of weight (kg) divided by height (in meters) squared. [0003] Overweight and obesity are associated with increasing the risk of developing many chronic diseases of aging seen in the U.S. Such co-morbidities include type 2 diabetes mellitus, hypertension, coronary heart diseases and dyslipidemia, gallstones and 20 cholecystectomy, osteoarthritis, cancer (of the breast, colon, endometrial, prostate, and gallbladder), and sleep apnea. It is estimated that there are around 325,000 deaths annually that are attributable to obesity. The key to reducing the severity of the diseases is to lose weight effectively. Although about 30 to 40% claim to be trying to lose weight or maintain lost weight, current therapies appear not to be working. Besides dietary manipulation, 25 pharmacological management and in extreme cases, surgery, are sanctioned adjunctive therapies to treat overweight and obese patients (Expert Panel, National Institute of Health, Heart. Lung, and Blood Institute, 1-42 (June 1998); Bray, G. A., Contemporary Diagnosis and Management of Obesity, 246-273 (1998)). Drugs have side effects, and surgery, although effective, is a drastic measure and reserved for morbidly obese. 30 [0004] Cachexia is wasting of both adipose and skeletal muscle mass caused by disease. It occurs in many conditions and is common with many cancers when remission or control fails. 1 WO 2011/161427 PCT/GB2011/000966 Patients with advanced cancer, AIDS, and some other major chronic progressive diseases may appear cachectic. Cachexia can occur in people who are eating enough, but who cannot absorb the nutrients. While cachexia may be mediated by certain cytokines, especially tumor necrosis factor-α, IL-lb, and IL-6, which are produced by tumor cells and host cells in the 5 tissue mass, there is currently no widely accepted treatment for cachexia. [0005] Diabetes mellitus is a major cause of morbidity and mortality. Chronically elevated blood glucose leads to debilitating complications: nephropathy, often necessitating dialysis or renal transplant; peripheral neuropathy; retinopathy leading to blindness; ulceration of the legs and feet, leading to amputation; fatty liver disease, sometimes progressing to cirrhosis; and 10 vulnerability to coronary artery disease and myocardial infarction. [0006] There are two primary types of diabetes. Type I, or insulin-dependent diabetes mellitus (IDDM) is due to autoimmune destruction of insulin-producing beta cells in the pancreatic islets. The onset of this disease is usually in childhood or adolescence. Treatment consists primarily of multiple daily injections of insulin, combined with frequent testing of 15 blood glucose levels to guide adjustment of insulin doses, because excess insulin can cause hypoglycemia and consequent impairment of brain and other functions. Increasing scrutiny is being given to the role of insulin resistance to the genesis, progression, and therapeutic management of this type of diabetic disease. [0007] Type II, or noninsulin-dependent diabetes mellitus (NIDDM) typically develops in 20 adulthood. NIDDM is associated with resistance of glucose-utilizing tissues like adipose tissue, muscle, and liver, to the actions of insulin. Initially, the pancreatic islet beta cells compensate by secreting excess insulin. Eventual islet failure results in decompensation and chronic hyperglycemia. Conversely, moderate islet insufficiency can precede or coincide with peripheral insulin resistance. There are several classes of drugs that are useful for treatment of 25 NIDDM: 1) insulin releasers, which directly stimulate insulin release, carrying the risk of hypoglycemia; 2) prandial insulin releasers, which potentiate glucose-induced insulin secretion, and must be taken before each meal; 3) biguanides, including metformin, which attenuate hepatic gluconeogenesis (which is paradoxically elevated in diabetes); 4) insulin sensitizers, for example the thiazolidinedione derivatives rosiglitazone and pioglitazone, 30 which improve peripheral responsiveness to insulin, but which have side effects like weight 2 WO 2011/161427 PCT/GB2011/000966 gain, edema, and occasional liver toxicity; 5) insulin injections, which are often necessary in the later stages of NIDDM when the islets have failed under chronic hyperstimulation. [0008] Insulin resistance can also occur without marked hyperglycemia, and is generally associated with atherosclerosis, obesity, hyperlipidemia, and essential hypertension. This 5 cluster of abnormalities constitutes the "metabolic syndrome" or "insulin resistance syndrome". Insulin resistance is also associated with fatty liver, which can progress to chronic inflammation (NASH; "nonalcoholic steatohepatitis"), fibrosis, and cinhosis. Cumulatively, insulin resistance syndromes, including but not limited to diabetes, underlie many of the major causes of morbidity and death of people over age 40. 10 [0009] Despite the existence of such drugs, diabetes remains a major and growing public health problem. Late stage complications of diabetes consume a large proportion of national health care resources. There is a need for new orally active therapeutic agents which effectively address the primary defects of insulin resistance and islet failure with fewer or milder side effects than existing drugs. 15 {0010] Zinc-ai-glycoprotein (ZAG) has been identified as a lipid mobilizing factor (LMF) with the potential to induce fat loss in cancer cacehxia. ZAG was shown to induce lipolysis in white adipocytes by interaction with a β3-adrenergic receptor, while in vivo it increased expression of uncoupling protein-1 (UCP-1) in brown adipose tissue (BAT), and induced loss of body fat. In addition to some tumors, ZAG is also produced by white adipose tissue 20 (WAT) and BAT and its expression is upregulated in cachexia. In contrast ZAG expression in adipose tissue of obese humans was only 30% of that found in non-obese subjects. This suggests that loss of ZAG expression in WAT could account for some of the features of obesity. Certainly inactivation of both ZAG alleles in mice led to an increase in body weight which was more pronounced when the animals were fed a high fat diet.